| Literature DB >> 18022391 |
Michiyo Deushi1, Mitsunori Nomura, Akio Kawakami, Mihoko Haraguchi, Mizuho Ito, Mitsuyo Okazaki, Hideto Ishii, Masayuki Yoshida.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is associated with the metabolic syndrome characterized by dislipidemia and insulin resistance. We hypothesized that ezetimibe, an inhibitor of NPC1L1, improves these metabolic disorders in Zucker obese fatty rats (ZOF). Ezetimibe significantly lowered total cholesterol and triglycerides in ZOF with prominent reduction in the remnant lipoprotein fraction and small dense low density lipoprotein fraction. Moreover, lipid deposition and fibrosis of liver were decreased by ezetimibe. Interestingly, ezetimibe improved insulin and plasma glucose response after intraperitoneal glucose injection. Further, ezetimibe enhanced insulin signaling in cultured hepatocytes. Our results indicate the potential of ezetimibe in treating the metabolic syndrome and NAFLD.Entities:
Mesh：
Substances：
Year: 2007 PMID： 18022391 DOI： 10.1016/j.febslet.2007.11.023
Source DB: PubMed Journal: FEBS Lett ISSN： 0014-5793 Impact factor: 4.124